What is Bristol-Myers Squibb's other legacy products — total revenues?

Bristol-Myers Squibb (BMY) reported other legacy products — total revenues of $177.00M in Q3 2025.

How has Bristol-Myers Squibb's other legacy products — total revenues changed year-over-year?

Bristol-Myers Squibb's other legacy products — total revenues decreased by 21.3% year-over-year, from $225.00M to $177.00M.

What is the long-term trend for Bristol-Myers Squibb's other legacy products — total revenues?

Over 2 years (2022 to 2024), Bristol-Myers Squibb's other legacy products — total revenues has grown at a -10.8% compound annual growth rate (CAGR), from $1.16B to $925.00M.

What does other legacy products — total revenues mean?

Total sales generated from older, mature pharmaceutical products that are no longer the primary growth drivers for the company.

Products & Services · Total Revenues

Other Legacy products — Total Revenues

Bristol-Myers Squibb Other Legacy products — Total Revenues decreased by 20.6% to $177.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 21.3%, from $225.00M to $177.00M. Over 2 years (FY 2022 to FY 2024), Other Legacy products — Total Revenues shows a downward trend with a -10.8% CAGR.

Analysis

StatementSegment

CategoryGrowth

SignalContext dependent

VolatilityModerate

First reportedQ1 2022

Last reportedQ3 2025

Rolls up toTotal Revenue

How to read this metric

A decrease in revenue is expected as products age and lose patent exclusivity, while a sudden increase might indicate successful lifecycle management or temporary market dynamics. A rapid decline may signal a need for faster innovation to offset the loss of legacy cash flows.

Detailed definition

This metric represents the aggregate revenue generated from the company's portfolio of mature pharmaceutical products th...

Peer comparison

Peers in the pharmaceutical industry typically report this as 'Established Brands' or 'Mature Products' revenue, which is generally expected to decline over time as a percentage of total sales.

Metric ID: bmy_segment_other_legacy_products_total_revenues

Historical Data

15 periods

	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25
Value	$290.50M	$290.50M	$290.50M	$290.50M	$246.00M	$248.00M	$237.00M	$231.00M	$228.00M	$222.00M	$225.00M	$250.00M	$199.00M	$223.00M	$177.00M
QoQ Change	—	+0.0%	+0.0%	+0.0%	-15.3%	+0.8%	-4.4%	-2.5%	-1.3%	-2.6%	+1.4%	+11.1%	-20.4%	+12.1%	-20.6%
YoY Change	—	—	—	—	-15.3%	-14.6%	-18.4%	-20.5%	-7.3%	-10.5%	-5.1%	+8.2%	-12.7%	+0.5%	-21.3%

Range$177.00M – $290.50M

CAGR-13.2%

Avg YoY Growth-10.6%

Median YoY Growth-12.7%

Similar Metrics at Other Companies

Eli LillyLLY View metric

AmgenAMGN View metric

AbbottABT View metric

Gilead SciencesGILD View metric

Frequently Asked Questions

What is Bristol-Myers Squibb's other legacy products — total revenues?: Bristol-Myers Squibb (BMY) reported other legacy products — total revenues of $177.00M in Q3 2025.
How has Bristol-Myers Squibb's other legacy products — total revenues changed year-over-year?: Bristol-Myers Squibb's other legacy products — total revenues decreased by 21.3% year-over-year, from $225.00M to $177.00M.
What is the long-term trend for Bristol-Myers Squibb's other legacy products — total revenues?: Over 2 years (2022 to 2024), Bristol-Myers Squibb's other legacy products — total revenues has grown at a -10.8% compound annual growth rate (CAGR), from $1.16B to $925.00M.
What does other legacy products — total revenues mean?: Total sales generated from older, mature pharmaceutical products that are no longer the primary growth drivers for the company.